Parallel Advisors LLC acquired a new stake in shares of Urogen Pharma Ltd (NASDAQ:URGN) during the third quarter, according to its most recent disclosure with the SEC. The fund acquired 1,500 shares of the company’s stock, valued at approximately $36,000.
Several other hedge funds also recently bought and sold shares of the company. United Services Automobile Association lifted its position in shares of Urogen Pharma by 0.9% during the 2nd quarter. United Services Automobile Association now owns 50,605 shares of the company’s stock valued at $1,819,000 after buying an additional 470 shares in the last quarter. Rhumbline Advisers lifted its holdings in Urogen Pharma by 4.4% in the 3rd quarter. Rhumbline Advisers now owns 22,010 shares of the company’s stock worth $524,000 after purchasing an additional 931 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in Urogen Pharma by 50.0% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,000 shares of the company’s stock worth $108,000 after purchasing an additional 1,000 shares in the last quarter. Altshuler Shaham Ltd lifted its holdings in Urogen Pharma by 4.8% in the 2nd quarter. Altshuler Shaham Ltd now owns 25,892 shares of the company’s stock worth $931,000 after purchasing an additional 1,194 shares in the last quarter. Finally, Bank Hapoalim BM lifted its holdings in Urogen Pharma by 4.9% in the 3rd quarter. Bank Hapoalim BM now owns 27,230 shares of the company’s stock worth $653,000 after purchasing an additional 1,260 shares in the last quarter. 70.33% of the stock is currently owned by hedge funds and other institutional investors.
In other Urogen Pharma news, CFO Peter P. Pfreundschuh sold 1,416 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $33.07, for a total value of $46,827.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 10.50% of the stock is currently owned by corporate insiders.
NASDAQ:URGN opened at $26.30 on Friday. The stock’s 50 day simple moving average is $23.01 and its two-hundred day simple moving average is $31.67. Urogen Pharma Ltd has a 1 year low of $20.72 and a 1 year high of $55.49. The company has a market cap of $574.88 million, a price-to-earnings ratio of -5.48 and a beta of 1.12.
Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Tuesday, November 12th. The company reported ($1.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.26) by $0.20. On average, equities research analysts expect that Urogen Pharma Ltd will post -4.92 EPS for the current fiscal year.
Urogen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Featured Story: How does inflation affect different investments?
Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma Ltd (NASDAQ:URGN).
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.